Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.

gammadelta T-cells have recently attracted considerable attention in the development of novel cancer immunotherapy, and several different approaches have been designed and employed in clinical trials. A patient with lung metastasis after radical nephrectomy for renal cell carcinoma had six cycles of adoptive immunotherapy using autologous in vitro-activated gammadelta T-cells followed by low-dose interleukin-2 and zoledronic acid intravenous infusion. Complete remission was achieved which has been maintained for 2 years without any additional treatment. Immunological analysis demonstrated a high level of interferon-gamma four hours through one day following the transfer and peripheral blood gammadelta T-cells increased 10-fold from the baseline value, 7 days after the transfer. No serious adverse events were observed. Adoptive immunotherapy using gammadelta T-cells was shown here to be clinically beneficial and safe, and may become a therapeutic option for patients with advanced RCC.